Clinical Trial Search

Primary: Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271) — 28.66; 30.58 percent change — p=0.358

Primary: Overall Survival (OS) — 22.8 Months

Primary: Incidence of Adverse Events, Serious Adverse Events, and Adverse Events Leading to Withdrawal. — 0; 1.2 percentage of participants

Primary: Change in HbA1c — -2.0; -2.2; -1.9; -2.2 Percentage change — p=0.0003

Primary: Change in Bacterial Microflora on the Inguinal Area — -3.7; -3.1; -3.5 log10 CFU

Primary: Change in Bacterial Microflora on the Inguinal Area — -3.92; -3.69; -3.94 log10 CFU

Primary: Change in Bacterial Microflora in the Inguinal Area — -3.86; -4.34; -3.65; -3.80 log10 CFU

Primary: Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Population — 95.2; 93.1…

Primary: Part A: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA — 6.13; 6.93; 1.01 microgram per milliliter (mcg/mL)

Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up

Primary: Ocular Sign: Change From Baseline in Total Corneal Staining Score to Day 14 — -1; -0.68 score on a scale

Primary: Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population — 0.665; 0.235…

Primary: Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52) — 1.02; 1.12 Grams per deciliter

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.87; -1.89; -2.07; 0.04 Percentage of HbA1c — p=<0.001

Primary: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 8.3; 4.2 Months